Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
Date:10/7/2008

- Planned 15 Patient Cohort Enrolled in Stage A of Trial Assessing Regimen

of Bavituximab in Combination With Carboplatin and Paclitaxel -

TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. This is Peregrine's second Phase II study for the treatment of breast cancer. The main objective of the multi-center, open-label safety and efficacy study is to assess patients' overall response rate to a regimen combining bavituximab with the chemotherapy drugs carboplatin and paclitaxel. Patients in the study are receiving the treatment regimen and are being evaluated regularly for tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Peregrine president and CEO, Steven W. King noted, "We are very pleased that the sites were able to rapidly complete enrollment in the first part of this important Phase ll study. We look forward to generating clinical data from both of our ongoing Phase ll studies in advanced breast cancer patients over the coming months that will enable us to better assess bavituximab's early potential as a novel targeted therapy for breast cancer."

As part of this trial's Simon two-stage design, 15 patients with advanced breast cancer have been enrolled in Stage A of the study. The trial may be expanded to include up to an additional 31 subjects if promising results are seen in the Stage A cohort. The primary ob
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
4. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
5. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
7. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
10. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Research and Markets ( ... "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services ... Asia Pacific Version" report to their offering. ... growing. Clinical laboratory testing is positioned to directly ... A range of dynamic trends are pushing market ...
(Date:5/5/2015)... 5, 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... months ended March 31, 2015 and reaffirmed its revenue, ... 2015. First Quarter 2015 Highlights Include: ... of 72% as compared to $10.9 million for the ... non-GAAP EBITDA of $11.5 million, an increase of 170% as ...
(Date:5/5/2015)...   Cynosure, Inc. (Nasdaq: CYNO ), ... procedures and precision surgical applications worldwide, today reported financial ... First-Quarter Highlights: , North America product ... of $0.15 per share; GAAP earnings break-even , ... 2015 "Cynosure delivered 21 percent year-over-year top-line ...
Breaking Medicine Technology:Asia Pacific Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Report 2015-2019 2ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 2ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 3ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 4ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 5ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 6ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 7ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 8ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11
... Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... treat voiding dysfunctions, today reported financial results for the fourth ... Global sales grew 35% to $4.0 million in the ... million in the fourth fiscal quarter a year ago.  The ...
... 25, 2011 Just days after the one year ... sales representatives at Novartis Pharmaceuticals Corporation, the law firm ... identical class action on behalf of female sales representatives ... the amended complaint, there is an entirely new class ...
Cached Medicine Technology:Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 2Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 3Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 4Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 5Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 6Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 7Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 8Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 9Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 10Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 11Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 2Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 3Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 4
(Date:5/5/2015)... (PRWEB) May 05, 2015 What do you ... one of the world’s greatest mountaineers and one of the ... Kilimanjaro is a 54-minute documentary by Marc Middleton, which follows ... and advocates to the 19,341-foot frozen summit of Mount Kilimanjaro. ... inspiration and a call to action. Viewers are moved to ...
(Date:5/5/2015)... 2015 Major League Ultimate (MLU) was ... that ultimate Frisbee™ is home to many amazing athletes, ... engages the world. Nike Ultimate Camps’ goal of spreading ... for young athletes to learn about the sport and ... perfect fit. , The Nike Ultimate Camp in Philadelphia ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 May is National ... the Institute for Better Bone Health . Founded by ... aims to educate both consumers and physicians about the latest ... of bone health. , According to a study recently published ... total Americans are affected by osteoporosis and low bone mass. ...
(Date:5/5/2015)... 2015 HealthSlide, Inc ., ... solutions for hospitals nationwide, has announced the launch ... CIOs and CTOs can access the calculator on ... both initial and ongoing savings of switching to ... nation’s hospitals pay an average of $300,000 a ...
(Date:5/5/2015)... 05, 2015 Crawford Technologies announced today it ... Colorado Chapter of the Business Marketing Association (BMA) ... Gold Key Award was presented to the CrawfordTech marketing team ... and Science with over 300 people in attendance. , “The ... March 2014 represented a shift in focus for how our ...
Breaking Medicine News(10 mins):Health News:LIVESTRONG & Bolder Broadcasting Present Special Edition of Conquering Kilimanjaro 2Health News:LIVESTRONG & Bolder Broadcasting Present Special Edition of Conquering Kilimanjaro 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 2Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 3Health News:HealthSlide Launches ROI Cost Calculator 2Health News:Crawford Technologies Awarded BMA’s ‘2015 Gold Key Award’ for Innovative Website Redesign 2Health News:Crawford Technologies Awarded BMA’s ‘2015 Gold Key Award’ for Innovative Website Redesign 3
... Jan. 27 Financing has become a,very popular way to ... after you have had your "nip and tuck", you are ... ways to get out of debt, and at the same,time ... Dr. Charles Mok , a ...
... have spotted DNA potentially linked to the disease , , ... they,ve spotted genetic "hot spots" associated with psoriasis, a ... tailored treatments for the autoimmune skin disease. , The ... patients and healthy people, and identified seven areas that ...
... system chosen needs to match needs, culture of staff , , ... hospital is, the lower its rate of patient deaths and ... also saves centers money, the researchers report. , Although there ... Herrick, senior fellow at the National Center for Policy Analysis ...
... The University of Nottingham is calling for urgent action ... growing number of repeat teenage pregnancies in the United ... and Wales from 1991 to 2007, provided by the ... at Nottingham found that the number of women under ...
... for the prevention of coronary heart disease, with ... at highest risk (ie, those with established heart ... estimation models may not be accurately achieved in ... groups whose 10-year "short-term" estimated risk seems low. ...
... Center Planned to Spur Energy Innovation and Job Creation ... located in the Houston, Texas region, will serve as ... as an accelerator for start-up companies. The initiative ... in the U.S. and recognized as a world leader ...
Cached Medicine News:Health News:Lay Away Plan for Cosmetic Surgery 2Health News:Gene Insights May Improve Psoriasis Care 2Health News:'Wired' Hospitals Post Lower Death, Complication Rates 2Health News:'Wired' Hospitals Post Lower Death, Complication Rates 3Health News:Repeat pregnancies among teenagers on the increase 2Health News:Assessing the real risk of heart disease in young people with low short-term risks 2Health News:Nano World Headquarters Positioned to Boost U.S. Economy 2Health News:Nano World Headquarters Positioned to Boost U.S. Economy 3Health News:Nano World Headquarters Positioned to Boost U.S. Economy 4
... up to 12 L/min of Type I ... Demand, The Super-Q Plus System is designed ... which has been pretreated by reverse osmosis, ... produce ultrapure water quality which exceeds Type ...
... System Produces Type I Water Directly from Tap, ... for scientists who need 5 to 15 L ... have easy access to acceptable quality pretreated water. ... L/min of ultrapure (Type I) water on demand, ...
... UniBloc weighing mechanism for speed, ... stability control, analog display modes, multiple ... percent measure functions, auto print, and ... data from built-in clock. Built-in, ...
TOPLOAD 320/0.01G, BL320S. Touch-key external calibration only. Requires calibration weights (either 200g or 300g). 120/240V A/C adapter, Lock-down Ring, In-use Protective Cover....
Medicine Products: